Next Article in Journal
Regulation of 4-HNE via SMARCA4 Is Associated with Worse Clinical Outcomes in Hepatocellular Carcinoma
Next Article in Special Issue
Activation and Regulation of Pancreatic Stellate Cells in Chronic Pancreatic Fibrosis: A Potential Therapeutic Approach for Chronic Pancreatitis
Previous Article in Journal
Hsp70—A Universal Biomarker for Predicting Therapeutic Failure in Human Female Cancers and a Target for CTC Isolation in Advanced Cancers
Previous Article in Special Issue
Gut Microbiota and Liver Transplantation: Immune Mechanisms behind the Rejection
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 8
10.3390/biomedicines11082277
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Skin and Gut Microbiome in Hidradenitis Suppurativa: A Systematic Review

by
Edyta Lelonek
1,*,
Dorra Bouazzi
2,
Gregor B. E. Jemec
2 and
Jacek C. Szepietowski
1
1
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland
2
Department of Dermatology, Zealand University Hospital, 4000 Roskilde, Denmark
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(8), 2277; https://doi.org/10.3390/biomedicines11082277
Submission received: 21 June 2023 / Revised: 2 August 2023 / Accepted: 4 August 2023 / Published: 16 August 2023
(This article belongs to the Special Issue Inflammasome and Microbiota Functions in Skin, Mouth, and Gut Inflammation)
Browse Figure
Review Reports Versions Notes

Abstract

:
Hidradenitis suppurativa (HS) is a chronic skin disease that significantly impairs the quality of life of affected individuals. The disease is characterized by persistent purulent lesions in specific anatomical areas, and its pathophysiology involves multiple factors, including inflammation, genetics, the microbiome, and environmental components. Recent research suggests a potential role for pathogenic bacteria in HS, highlighting the importance of the communication between the human host and the microbiome in maintaining homeostasis and immune system reactivity. However, the exact mechanisms underlying the gut–skin microbial interactions in HS remain unclear. This systematic review aims to examine the existing literature on the differences in skin and gut microbiome composition between HS patients and healthy controls. The review identifies methodological inconsistencies and calls for further research to elucidate the microbiome’s role in HS pathogenesis and to explore new therapeutic interventions. The review highlights the need for advancements in microbiome research methodologies, such as metataxonomics and metagenomics, to improve our understanding of the microbiota’s impact on health and disease.

1. Introduction

Hidradenitis suppurativa (HS) is a chronic autoinflammatory skin disease with persistently draining purulent lesions in intertriginous anatomical sites, such as the axilla, groin, and gluteal areas, leading to significantly impaired quality of life (QoL) due to the physical and psychological symptoms [1,2,3]. The pathophysiology of HS is multifactorial, with contributing factors including inflammation, genetic tendency, the microbiome, and environmental components. According to the classical postulate, the disease is initiated by follicular occlusion followed by the formation of inflammatory lesions and secondary bacterial infection [4].
New understanding of HS has begun to include a potential role for pathogenic bacteria. There is increasing evidence that the continuous crosstalk between humans and the microbiome is critical for establishment and maintenance of host homeostasis [5]. Alterations in microbiome composition could shift it towards dysbiosis—an abnormal state leading to modifications in immune system reactivity and subsequently to inflammatory disease development [6]. Emerging evidence supports the existence of the microbiome role in the pathogenesis of various cutaneous disorders, including psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne, emphasizing the presence of communication axes between the gut and skin [7]. However, the exact mechanism underlying gut–skin microbial interactions has not yet been fully elucidated [8]. One of the therapeutic modalities in HS is the usage of antibiotics with known additional anti-inflammatory effects, for which the role of their antimicrobial action on the microbiome specifically is still unclear [9].
In recent years, advancements in the understanding of the complex relationship between the skin and gut microbiome have led to a thorough exploration of the microbiota composition. However, the association of HS with skin and/or gut dysbiosis is mainly based on limited studies with small numbers of patients involved. Thus, in this review, we scrutinize the existence of literature with regard to how the skin and gut microbiome in HS patients differs from that in healthy controls. Furthermore, the study aims to identify current methodological inconsistencies and outline directions for future research, which can contribute to the introduction of new strategic therapeutic interventions.

2. Methods

The systematic review was prospectively registered with PROSPERO (Registration Number CRD42022331681) and was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Figure 1) [10]. The primary outcome measure of our study was a systematic review of previous studies investigating the skin and gut microbiome of patients with hidradenitis suppurativa. Discrepancies between investigators at every stage were thoroughly discussed by all authors until a consensus was reached.

2.1. Search Strategy

Studies were identified by searching electronic databases and scanning reference lists of articles. We searched four electronic databases from 1992 to May 2022: MEDLINE (via PubMed), Embase (via OvidSP), Web of Science Core Collection, and Google Scholar. To identify studies comparing skin and gut microbiome composition in patients with HS and normal healthy controls, the combination of the following keywords was included: “hidradenitis suppurativa”, “acne inversa”, “microbiome”, “microbiota”, “bacteriology”, “dysbiosis”, and “gut”. The Boolean operators used were “AND” and “OR”. Moreover, the reference sections of relevant articles were manually scanned for additional relevant studies. The database search was undertaken independently by two reviewers for each database. The titles and abstracts of articles retrieved by the search strategy were reviewed independently by two of the authors.

2.2. Inclusion/Exclusion Criteria

The inclusion criteria are as follows:
  • Subjects aged 18 years or older;
  • Human studies investigating the association between gut and/or skin microbiota and hidradenitis suppurativa;
  • Articles published in English.
We excluded from the analysis articles not written in the English language, reviews, editorial letters, conference abstracts, expert opinions, and studies using animal models.

2.3. Study Selection

Two authors (E.L., D.B.) independently reviewed the titles and abstracts of all papers retrieved by the search strategy. Relevant full-text articles were evaluated for fulfilling the inclusion and exclusion criteria.

2.4. Quality Assessment

The evaluation of case-control studies was carried out according to the Newcastle–Ottawa Scale (NOS), which is an effective tool for quality assessment. The estimation of the three categories was performed as follows: selection (adequate case definition, representativeness of the cases, selection of controls, definition of controls); comparability (factors that the study controlled for by design or analysis to improve the comparability of baseline characteristics of cases and controls); exposure (ascertainment of exposure, same method of ascertainment for cases and controls, nonresponse rate).

2.5. Data Extraction

Two authors (E.L., D.B.) extracted the following data from the eligible studies in an independent manner: first author, publication year, country where the study was conducted, participant characteristics (sample size, age, sex, current treatment), sample materials, DNA extraction method, 16S rRNA variable region, sequencing platform, data analysis platform, reference sequences database employed in the studies, microbial diversity, alterations in the skin and gut microbiota in patients with HS.

3. Results

3.1. Search Results and Study Characteristics

Twenty-six records were included for the final investigation. The details of the article selection process are shown in Figure 1.
All eligible studies were published between 1996 and 2021 [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]. The total sample size of included studies was 1628 (1419 patients with HS and 209 healthy controls).
The five tables were constructed including the main findings from each incorporated study (Table 1, Table 2, Table 3, Table 4 and Table 5).
Twenty-five studies examining the cutaneous microbiome and five studies examining the gastrointestinal microbiome in HS were identified. A total of 1274 patients and 123 healthy controls were included across studies examining the cutaneous microbiome. A total of 145 patients and 86 controls were included across gut microbiome studies.

3.2. The Cutaneous Microbiome in Hidradenitis Suppurativa

See Table 1, Table 2, Table 3 and Table 4.

3.3. The Gastrointestinal Microbiome

See Table 5.

3.4. The Oral Microbiome

No studies were identified which examined the oral microbiome in HS.

3.5. Quality of the Evidence

All included studies were assessed for quality according to NOS and scored between 2 to 9 points (Table 1, Table 2, Table 3, Table 4 and Table 5).

4. Discussion

4.1. The Human Microbiota and Skin Microbiome

The human microbiota refers to microorganisms found on humans. It is composed of communities of bacteria, viruses, and fungi and is known to have a greater complexity than the human genome itself. The collective microbiota together with its inhabitation of a certain environment is called microbiome. The composition of the human microbiome suggests that the most of it consists of the commensal microorganism, predominantly bacteria, and the disruption of this changeable homeostasis could lead to dysbiosis. Considering that the microbiome balance is crucial for the immune system development, any unevenness can contribute to disruption in communication between the microbiome and the host [37]. The skin microbiome is constantly influenced by various exogenous and environmental factors, such as skin-care products, clothing, humidity, temperature of the surrounding climate, and ultraviolet light exposure. Moreover, certain studies demonstrate that there is a large variability in the density and types of bacteria forming the microbiome, dependent on characteristics such as age, sexual maturity, anatomical location (i.e., face, trunk, extremities), skin pH, personal hygiene, and topography of the area, including hair, sebaceous glands, and moisture [5,6,38,39].

4.2. Gut–Skin Axis

In 1907, Metchnikoff hypothesized that overall health and longevity are intimately linked to the gut microbiota [40]. Considering the huge immunological impact and metabolic capacity of the gut microbiota, it is postulated that the gut microbiota is the essential part of the gut–skin axis (GSA). In this particular connection, the gut can enhance skin health via modulation of the immune environment through the microbiota. Regardless of multiple studies support the existence of GSA, the causative nature of the relationship between the gut microbiome and dermatologic conditions still is not elucidated. For instance, almost one-fourth of patients with conditions primarily affecting the gut also suffers from associated cutaneous findings, mainly psoriasis and cutaneous ulcers [41,42].
Various hypotheses propose a common argument suggesting that inflammation, originating from intestinal dysbiosis in the gut or skin, may trigger negative effects on the skin through the GSA [43]. Additionally, a theory indicates that bacteria migrate directly from the gut to other organs, and circulation occurs due to increased intestinal permeability [44]. Multiple studies have found an elevated presence of gut bacterial DNA in the bloodstream of patients with chronic skin conditions, which contributes to the inflammatory response [45]. The neuroendocrine link between the gut and skin microbiome is facilitated by gut microorganisms producing neurotransmitters such as norepinephrine, serotonin, and acetylcholine. This leads to the stimulation of neural pathways, resulting in the release of hormones from enteroendocrine cells, causing widespread systemic effects and inflammation, ultimately affecting the skin.

4.3. Methodology

A remarkable increase in research on the microbiome in recent years can be attributed to advancements in the field’s methodology. Two major sequencing-based techniques used for microbiome research are metataxonomics and metagenomics [46]. The first one involves sequencing specific marker genes, such as 16S rRNA or the internal transcribed spacer 1 (ITS1), that have hypervariable regions for identifying species and conserved regions for targeting with universal primers [47]. This method is quick and cost-effective, but it cannot detect viral sequences and has limited resolution. On the other hand, metagenomics involves sequencing all genetic material in a sample without prior locus selection, allowing for de novo genome assembly and high-resolution analysis of species and strains. However, it requires a high read count and alignment to a reference genome for classification and may also capture reads from the host organism. Multi-omics approaches, including transcriptomic, proteomic, and metabolomic data, can supplement sequencing data for a more comprehensive understanding of microbial communities [48]. As these techniques continue to develop, they hold promise for advancing biomarker discovery and treatment development for various health conditions.
As the integration of multi-dimensional datasets becomes more sophisticated, our understanding of microbiota biology in relation to health and disease is expected to improve, which could lead to advancements in biomarker discovery or the development of new treatments.

4.4. Research

The majority of the studies presented in Table 1 found a decrease in the diversity of the microbiome in HS patients compared to healthy controls. For example, Schneider et al. (2017) [22] reported a significant loss of variety in HS patients compared to healthy controls, and Guet-Revillet et al. (2017) [24] found that anaerobes were increased in lesional skin of HS patients.
Other studies found differences in specific bacterial taxa between HS sufferers and the control group. For instance, Lam et al. (2021) [11] found that Mesorhizobium was increased in lesional skin of HS patients compared to healthy controls, and Ring et al. (2017) [19] reported that Porphyromonas and Peptoniphilus were more abundant in HS skin than healthy skin. Naik et al. (2020) [14] found that Cutibacterium spp. were decreased in HS patients, while Gram-negative Porphyromonadeacea, Prevotellaceae, Fusobacteria, and positive anaerobes (Clostridales) were increased in the HS group.
Some studies also found that the microbiota in different body sites or skin niches of HS patients are less diverse and more similar to each other than in healthy controls. For example, Schneider et al. (2020) [22] reported a loss of heterogeneity between body sites and skin niches in HS patients. McCarthy et al. (2022) [12] found that Finegoldia magna was increased in groin and axilla of HS patients but decreased in nasal swabs of HS patients.
The research that used traditional culture methods (Table 2) also found differences in the bacterial composition of HS patients compared to healthy controls. The major findings include the identification of Staphylococcus aureus, Diphtheroid, Escherichia coli, and coagulase-negative staphylococci as the most common bacteria in HS patients, as well as the correlation between higher Hurley stages and more polymicrobial flora in culture-based studies.
Table 3 presents the results of (PNA)-FISH and CLSM studies on skin microbiota in patients with HS and healthy subjects. The studies utilized punch biopsy samples of clinically unaffected HS skin and employed PNA-FISH and CLSM examinations to assess bacterial aggregates and diversity. The major findings include the absence of bacterial aggregates at the stratum corneum and in hair follicles of preclinical HS skin. Only 12% of HS samples were categorized as positive for bacterial aggregates, while a morphologically significant presence of bacterial aggregates was observed in 92% of the healthy controls.
Table 4 presents the results of FISH, histology, and IF studies on skin microbiota in HS patients compared to healthy controls. The studies used tissue samples to examine bacterial colonization and utilized techniques such as histology and immunofluorescence (IF). The major findings include 63% of the HS patients being positive for bacterial colonization based on histological analysis. DAPI-labeled coccoids were observed in 71% of the positive patients, predominantly in the form of biofilms and microcolonies. Specifically, P. acnes was found as biofilms in hair follicles of two patients, while Staphylococcus aureus and coagulase-negative staphylococci were not detected in any of the samples.
The results presented in Table 5 summarize the findings from five metagenomic sequencing studies investigating the gut microbiota in both of the studied groups. These studies employed different sample types and sequencing regions and measured α- and β-diversity to explore the differences in the composition and structure of the gut microbiota between the two groups.
Collectively, these findings highlight that HS is associated with alterations in the gut microbiota composition, characterized by changes in specific bacterial species and reduced overall microbial diversity. The presence of certain bacterial species, such as Robinsoniella peoriensis, Bilophila, Holdemania, and Ruminococcus callidus, suggests potential roles in the pathogenesis of HS.

4.5. Limitations and Correlations

The concept of a “normal” cutaneous microbiome is still in the developmental stage and primarily differs based on the anatomical location of the skin rather than ethnicity or the use of typical topical products. The Human Microbiome Project is currently analyzing the “normal” human microbiome in various anatomical settings, including the skin. However, the existence of a true “normal” microbiome is unlikely, and it is expected to vary within and across individuals over time. Hence, comparing the results with “normal healthy” controls could introduce biases in identifying the findings [49,50].
There are several limitations in microbiome research related to HS. Most studies lack patient demographic data, such as smoking status and body mass index (BMI), which have demonstrated an impact on the intestinal microbiome, causing reduced diversity and alterations in commensal bacteria [51]. Additionally, the methodology employed in these studies varied, including the way specimens were obtained and the identification of bacteria, leading to differences in the bacteria identified on normal skin. Therefore, future studies must include adequate metadata related to age, sex, ethnicity, disease severity, anatomical location, concomitant medication, prior or concurrent antibiotic use, and topical product use to avoid confounding factors [52].
The investigation of microbiome alterations in HS among individuals with distinct body composition phenotypes has shed light on intriguing findings. HS has been associated with obesity, prompting researchers to explore the potential influence of body composition on the microbiome in this condition. This proffers valuable insights into the interplay between HS pathogenesis and the composition of the microbial communities inhabiting the human body.
Research indicates that HS patients with obesity exhibit notable differences in their microbiome compared to nonobese individuals with HS. These differences encompass alterations in both the gut and skin microbiota. Obese HS patients tend to exhibit dysbiosis, characterized by imbalances in microbial diversity, composition, and functionality. It is postulated that these dysbiotic changes in the microbiome could contribute to the chronic inflammatory state and the clinical manifestations observed in obese individuals with HS.
Specific bacterial taxa have been implicated in the altered microbiome of HS patients with obesity. The increased abundance of certain taxa, such as Staphylococcus species, has been observed in the skin microbiota of obese HS patients. Furthermore, dysregulation of bacterial species, including Prevotella and Bacteroides, has been noted in the gut microbiota of these individuals.
Conversely, nonobese HS patients display distinct microbiome characteristics compared to their obese counterparts. While there may still be some degree of dysbiosis, the specific taxa involved and the extent of microbial perturbations may differ. The microbial alterations in nonobese HS patients may be more subtle and nuanced, requiring further investigation to fully elucidate their implications for disease pathogenesis.
Understanding the microbiome changes associated with different body composition phenotypes in HS can have significant implications for patient management [29,53].
The identification of specific microbial signatures associated with HS has raised the possibility of utilizing the microbiome as a biomarker for this condition. By analyzing the composition and relative abundance of key bacterial taxa, it may be possible to develop microbiome-based biomarkers that can aid in the diagnosis and stratification of HS patients. Furthermore, studying the dynamics of the microbiome over time may offer insights into disease progression and treatment response. Additional investigation is warranted to better understand the significance of bacterial-based biomarkers in the context of HS, considering the well-established association between HS and bacterial dysbiosis. Several studies have highlighted the presence of inflammatory markers in HS, and it is acknowledged that the expression of these markers may be influenced by the presence or absence of specific microorganisms. Therefore, it is essential to conduct future studies that correlate tissue and serum inflammatory profiles with microbiome analyses to ascertain the clinical relevance and potential coexistence of bacterial dysbiosis with identified immunological alterations in HS. Such research endeavors will provide valuable insights into the intricate interplay between the microbiome and immune dysregulation in HS [54].
Additionally, the methodology employed in these studies varied, including the way specimens were obtained and the identification of bacteria, leading to differences in the bacteria identified on normal skin. Therefore, future studies must include adequate metadata related to age, sex, ethnicity, disease severity, anatomical location, concomitant medication, prior or concurrent antibiotic use, and topical product use to avoid confounding factors [29].
Cultures are crucial in identifying bacteria, particularly in clinical settings, but they have limitations as it is estimated that 99% of bacteria cannot be grown on culture [55]. The use of 16S is beneficial in identifying an array of bacteria compared to the traditional bacterial culture, but it cannot shed light on bacterial activity, host response, or interactions between host and microbe. Therefore, further research using whole-genome sequencing and RNA transcriptomics responses is necessary to better understand bacterial activity and the interplay between the organism and host gene expression [56]. Furthermore, standardization of approaches to collect affected and unaffected tissue within and across participants and associated baseline patient data is crucial to interpretation of data and minimizing confounding factors [57].
Biofilms and their role in HS pathogenesis are outside the scope of this review article but are still significant triggers in the organism-host pathophysiological response and deserve a mention in the discussion. HS is a disease characterized by biofilm formation, which may be significant in triggering the host pathophysiological response [58].

5. Conclusions

The human skin is a unique environment that presents challenges for microbial studies due to its low microbial biomass, high risk of contamination, and diverse range of site-specific microorganisms. To avoid bias, it is crucial for researchers and clinicians to acknowledge that there are several factors that may limit the comparability of microbiome research, such as variations in sampling and methodology between studies, as well as laboratory factors during DNA extraction and downstream processing.
Collectively, the findings demonstrate that HS is associated with dysbiosis in the skin microbiome, characterized by reduced microbial diversity, specific bacterial taxa differences, similarity within body sites, and alterations in the gut microbiota. These insights contribute to our understanding of the potential role of microbiota in the pathogenesis of HS and may guide future research and therapeutic approaches targeting the microbiome.

Author Contributions

Conceptualization, E.L. and G.B.E.J.; Methodology, E.L. and D.B.; Software, E.L.; Validation, E.L., G.B.E.J. and J.C.S.; Formal Analysis, E.L., D.B., G.B.E.J. and J.C.S.; Investigation, E.L. and D.B.; Resources, E.L. and D.B.; Data Curation, E.L.; Writing—Original Draft Preparation, E.L.; Writing—Review and Editing, E.L. and D.B.; Visualization, E.L.; Supervision, G.B.E.J. and J.C.S.; Project Administration, E.L.; Funding Acquisition, J.C.S. All authors have read and agreed to the published version of the manuscript.

Funding

The study was funded by a research grant from Wroclaw Medical University (SUBZ.C260.23.041). No funding or sponsorship was received for the publication of this article.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: https://www.ncbi.nlm.nih.gov/pmc/.

Acknowledgments

I would like to acknowledge the exceptional contributions and support of the doctors employed at the Dermatology Clinic in Roskilde, particularly Gregor Jemec and Dora Bouazzi. Their expertise, guidance, and dedication have been instrumental in the successful completion of this research. We are also grateful to the entire clinic staff for their cooperation, as their involvement has significantly contributed to advancing this review.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Jemec, G.B.E.; Revuz, J.; Leyden, J.J. (Eds.) Hidradenitis Suppurativa; Springer: Berlin, Germany, 2006. [Google Scholar]
  2. Emtestam, L.; Desai, N.; Hunger, R.; Zouboulis, C.C.; Ioannides, D.; Van Der Zee, H.H.; Prens, E.P.; E Jemec, G.B.; Schneider-Burrus, S.; Revuz, J.; et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 619–644. [Google Scholar] [CrossRef]
  3. Lelonek, E.; Bieniek, A.; Szepietowski, J. Improved Psychosocial Status after Surgery for Genital Elephantiasis due to Hidradenitis Suppurativa: A Prospective Study of a Case Series. Acta Derm. Venereol. 2021, 101, adv00389. [Google Scholar] [CrossRef]
  4. Napolitano, M.; Megna, M.; A Timoshchuk, E.; Patruno, C.; Balato, N.; Fabbrocini, G.; Monfrecola, G. Hidradenitis suppurativa: From pathogenesis to diagnosis and treatment. Clin. Cosmet. Investig. Dermatol. 2017, 10, 105–115. [Google Scholar] [CrossRef] [PubMed]
  5. Sinha, S.; Lin, G.; Ferenczi, K. The skin microbiome and the gut-skin axis. Clin. Dermatol. 2021, 39, 829–839. [Google Scholar] [CrossRef]
  6. Balato, A.; Cacciapuoti, S.; Di Caprio, R.; Marasca, C.; Masarà, A.; Raimondo, A.; Fabbrocini, G. Human Microbiome: Composition and Role in Inflammatory Skin Diseases. Arch. Immunol. Ther. Exp. 2019, 67, 1–18. [Google Scholar] [CrossRef] [PubMed]
  7. Arck, P.; Handjiski, B.; Hagen, E.; Pincus, M.; Bruenahl, C.; Bienenstock, J.; Paus, R. Is there a ‘gut-brain-skin axis’? Exp. Dermatol. 2010, 19, 401–405. [Google Scholar] [CrossRef] [PubMed]
  8. Ellis, S.R.; Nguyen, M.; Vaughn, A.R.; Notay, M.; Burney, W.A.; Sandhu, S.; Sivamani, R.K. The skin and gut microbiome and its role in common dermatologic conditions. Microorganisms 2019, 7, 550. [Google Scholar] [CrossRef] [PubMed]
  9. Frew, J.W.; Hawkes, J.E.; Krueger, J.G. Topical, systemic and biologic therapies in hidradenitis suppurativa: Pathogenic insights by examining therapeutic mechanisms. Ther. Adv. Chronic. Dis. 2019, 10, 2040622319830646. [Google Scholar] [CrossRef] [PubMed]
  10. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009, 339, b2535. [Google Scholar] [CrossRef]
  11. Lam, S.Y.; Radjabzadeh, D.; Eppinga, H.; Nossent, Y.R.A.; van der Zee, H.H.; Kraaij, R.; Konstantinov, S.R.; Fuhler, G.M.; Prens, E.P.; Thio, H.B.; et al. A microbiome study to explore the gut-skin axis in hidradenitis suppurativa. J. Dermatol. Sci. 2021, 101, 218–220. [Google Scholar] [CrossRef]
  12. McCarthy, S.; Barrett, M.; Kirthi, S.; Pellanda, P.; Vlckova, K.; Tobin, A.-M.; Murphy, M.; Shanahan, F.; O’toole, P.W. Altered Skin and Gut Microbiome in Hidradenitis Suppurativa. J. Investig. Dermatol. 2022, 142, 459–468.e15. [Google Scholar] [CrossRef] [PubMed]
  13. Eppinga, H.; Sperna Weiland, C.J.; Thio, H.B.; van der Woude, C.J.; Nijsten, T.E.; Peppelenbosch, M.P.; Konstantinov, S.R. Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. J. Crohns Colitis 2016, 10, 1067–1075. [Google Scholar] [CrossRef] [PubMed]
  14. Naik, H.B.; Jo, J.-H.; Paul, M.; Kong, H.H. Skin Microbiota Perturbations Are Distinct and Disease Severity–Dependent in Hidradenitis Suppurativa. J. Investig. Dermatol. 2020, 140, 922–925.e3. [Google Scholar] [CrossRef] [PubMed]
  15. Katoulis, A.C.; Koumaki, D.; Liakou, A.I.; Vrioni, G.; Koumaki, V.; Kontogiorgi, D.; Tzima, K.; Tsakris, A.; Rigopoulos, D. Aerobic and Anaerobic Bacteriology of Hidradenitis Suppurativa: A Study of 22 Cases. Ski. Appendage Disord. 2015, 1, 55–59. [Google Scholar] [CrossRef]
  16. Guet-Revillet, H.; Coignard-Biehler, H.; Jais, J.-P.; Quesne, G.; Frapy, E.; Poirée, S.; Le Guern, A.-S.; Le Flèche-Matéos, A.; Hovnanian, A.; Consigny, P.-H.; et al. Bacterial Pathogens Associated with Hidradenitis Suppurativa, France. Emerg. Infect. Dis. 2014, 20, 1990–1998. [Google Scholar] [CrossRef]
  17. Riverain-Gillet, É.; Guet-Revillet, H.; Jais, J.-P.; Ungeheuer, M.-N.; Duchatelet, S.; Delage, M.; Lam, T.; Hovnanian, A.; Nassif, A.; Join-Lambert, O. The Surface Microbiome of Clinically Unaffected Skinfolds in Hidradenitis Suppurativa: A Cross-Sectional Culture-Based and 16S rRNA Gene Amplicon Sequencing Study in 60 Patients. J. Investig. Dermatol. 2020, 140, 1847–1855.e6. [Google Scholar] [CrossRef]
  18. Ring, H.C.; Thorsen, J.; Saunte, D.M.; Lilje, B.; Bay, L.; Riis, P.T.; Larsen, N.; Andersen, L.O.; Nielsen, H.V.; Miller, I.M.; et al. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol. 2017, 153, 897–905. [Google Scholar] [CrossRef]
  19. Ring, H.C.; Bay, L.; Kallenbach, K.; Miller, I.M.; Prens, E.; Saunte, D.M.; Bjarnsholt, T.; Jemec, G.B. Normal Skin Microbiota is Altered in Pre-clinical Hidradenitis Suppurativa. Acta Derm. Venereol. 2017, 97, 208–213. [Google Scholar] [CrossRef]
  20. Ring, H.; Sigsgaard, V.; Thorsen, J.; Fuursted, K.; Fabricius, S.; Saunte, D.; Jemec, G. The microbiome of tunnels in hidradenitis suppurativa patients. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 1775–1780. [Google Scholar] [CrossRef]
  21. Benzecry, V.; Grancini, A.; Guanziroli, E.; Nazzaro, G.; Barbareschi, M.; Marzano, A.V.; Muratori, S.; Veraldi, S. Hidradenitis suppurativa/acne inversa: A prospective bacteriological study and review of the literature. G. Ital. Di Dermatol. E Venereol. 2020, 155, 459–463. [Google Scholar] [CrossRef]
  22. Schneider, A.M.; Cook, L.C.; Zhan, X.; Banerjee, K.; Cong, Z.; Imamura-Kawasawa, Y.; Gettle, S.L.; Longenecker, A.L.; Kirby, J.S.; Nelson, A.M. Loss of Skin Microbial Diversity and Alteration of Bacterial Metabolic Function in Hidradenitis Suppurativa. J. Investig. Dermatol. 2020, 140, 716–720. [Google Scholar] [CrossRef]
  23. Jahns, A.C.; Killasli, H.; Nosek, D.; Lundskog, B.; Lenngren, A.; Muratova, Z.; Emtestam, L.; Alexeyev, O.A. Microbiology of hidradenitis suppurativa (acne inversa): A histological study of 27 patients. Apmis 2014, 122, 804–809. [Google Scholar] [CrossRef] [PubMed]
  24. Guet-Revillet, H.; Jais, J.-P.; Ungeheuer, M.-N.; Coignard-Biehler, H.; Duchatelet, S.; Delage, M.; Lam, T.; Hovnanian, A.; Lortholary, O.; Nassif, X.; et al. The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study. Clin. Infect. Dis. 2017, 65, 282–291. [Google Scholar] [CrossRef] [PubMed]
  25. Jamalpour, M.; Saki, N.; Nozari, F. Microbial profile and antibiotic susceptibility of bacteria isolated from patients with hidradenitis suppurativa. Iran J. Dermatol. 2019, 22, 25–29. [Google Scholar]
  26. Nikolakis, G.; Liakou, A.; Bonovas, S.; Seltmann, H.; Bonitsis, N.; Join-Lambert, O.; Wild, T.; Karagiannidis, I.; Zolke-Fischer, S.; Langner, K.; et al. Bacterial Colonization in Hidradenitis Suppurativa/Acne Inversa: A Cross-sectional Study of 50 Patients and Review of the Literature. Acta Derm. Venereol. 2017, 97, 493–498. [Google Scholar] [CrossRef]
  27. Thomas, C.; Rodby, K.A.; Thomas, J.; Shay, E.; Antony, A.K. Recalcitrant Hidradenitis Suppurativa: An Investigation of Demographics, Surgical Management, Bacterial Isolates, Pharmacologic Intervention, and Patient-reported Health Outcomes. Am. Surg. 2016, 82, 362–368. [Google Scholar] [CrossRef]
  28. Hessam, S.; Sand, M.; Georgas, D.; Anders, A.; Bechara, F.G. Microbial Profile and Antimicrobial Susceptibility of Bacteria Found in Inflammatory Hidradenitis Suppurativa Lesions. Ski. Pharmacol. Physiol. 2016, 29, 161–167. [Google Scholar] [CrossRef]
  29. Haskin, A.; Fischer, A.H.; Okoye, G.A. Prevalence of Firmicutes in Lesions of Hidradenitis Suppurativa in Obese Patients. JAMA Dermatol. 2016, 152, 1276–1278. [Google Scholar] [CrossRef]
  30. Bettoli, V.; Manfredini, M.; Massoli, L.; Carillo, C.; Barozzi, A.; Amendolagine, G.; Ruina, G.; Musmeci, D.; Libanore, M.; Curtolo, A.; et al. Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 930–936. [Google Scholar] [CrossRef]
  31. Matusiak, Ł.; Bieniek, A.; Szepietowski, J. Bacteriology of Hidradenitis Suppurativa—Which Antibiotics are the Treatment of Choice? Acta Derm. Venereol. 2014, 94, 699–702. [Google Scholar] [CrossRef]
  32. Sartorius, K.; Killasli, H.; Oprica, C.; Sullivan, A.; Lapins, J. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br. J. Dermatol. 2012, 166, 879–883. [Google Scholar] [CrossRef]
  33. Lapins, J.; Jarstrand, C.; Emtestam, L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br. J. Dermatol. 1999, 140, 90–95. [Google Scholar] [CrossRef] [PubMed]
  34. Brook, I.; Frazier, E.H. Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J. Med. Microbiol. 1999, 48, 103–105. [Google Scholar] [CrossRef] [PubMed]
  35. Jemec, G.; Faber, M.; Gutschik, E.; Wendelboe, P. The Bacteriology of Hidradenitis suppurativa. Dermatology 1996, 193, 203–206. [Google Scholar] [CrossRef] [PubMed]
  36. Kam, S.; Collard, M.; Lam, J.; Alani, R.M. Gut Microbiome Perturbations in Patients with Hidradenitis Suppurativa: A Case Series. J. Investig. Dermatol. 2021, 141, 225–228.e2. [Google Scholar] [CrossRef]
  37. Amon, P.; Sanderson, I. What is the microbiome? Arch. Dis. Child. Educ. Pract. Ed. 2017, 102, 257–260. [Google Scholar] [CrossRef]
  38. Gallo, R.L. Human Skin Is the Largest Epithelial Surface for Interaction with Microbes. J. Investig. Dermatol. 2017, 137, 1213–1214. [Google Scholar] [CrossRef]
  39. Dréno, B.; Araviiskaia, E.; Berardesca, E.; Gontijo, G.; Sanchez Viera, M.; Xiang, L.F.; Martin, R.; Bieber, T. Microbiome in healthy skin, update for dermatologists. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 2038–2047. [Google Scholar] [CrossRef]
  40. Metchnikoff, E. The Prolongation of Life: Optimistic Studies; Mitchell, P., Ed.; GP Putnam’s Sons: NewYork, NY, USA, 1910; p. 96. [Google Scholar]
  41. O’Neill, C.A.; Monteleone, G.; McLaughlin, J.T.; Paus, R. The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays 2016, 38, 1167–1176. [Google Scholar] [CrossRef]
  42. Saarialho-Kere, U. The gut-skin axis. J. Pediatr. Gastroenterol. Nutr. 2004, 39 (Suppl. 3), S734–S735. [Google Scholar] [CrossRef]
  43. Belkaid, Y.; Tamoutounour, S. The influence of skin microorganisms on cutaneous immunity. Nat. Rev. Immunol. 2016, 16, 353–366. [Google Scholar] [CrossRef]
  44. Barker, N. Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 2014, 15, 19–33. [Google Scholar] [CrossRef] [PubMed]
  45. Gee, J.; Wortley, G.; Johnson, I.; Price, K.; Rutten, A.; Houben, G.; Penninks, A. Effects of saponins and glycoalkaloids on the permeability and viability of mammalian intestinal cells and on the integrity of tissue preparations in vitro. Toxicol. Vitr. 1996, 10, 117–128. [Google Scholar] [CrossRef] [PubMed]
  46. Marchesi, J.R.; Ravel, J. The vocabulary of microbiome research: A proposal. Microbiome 2015, 3, 31. [Google Scholar] [CrossRef] [PubMed]
  47. Schoch, C.L.; Seifert, K.A.; Huhndorf, S.; Robert, V.; Spouge, J.L.; Levesque, C.A.; Chen, W.; Fungal Barcoding Consortium; Fungal Barcoding Consortium Author List; Bolchacova, E.; et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc. Natl. Acad. Sci. USA 2012, 109, 6241–6246. [Google Scholar] [CrossRef]
  48. Baldrian, P.; López-Mondéjar, R. Microbial genomics, transcriptomics and proteomics: New discoveries in decomposition research using complementary methods. Appl. Microbiol. Biotechnol. 2014, 98, 1531–1537. [Google Scholar] [CrossRef]
  49. Gevers, D.; Knight, R.; Petrosino, J.F.; Huang, K.; McGuire, A.L.; Birren, B.W.; Nelson, K.E.; White, O.; Methé, B.A.; Huttenhower, C. The Human Microbiome Project: A Community Resource for the Healthy Human Microbiome. PLoS Biol. 2012, 10, e1001377. [Google Scholar] [CrossRef]
  50. Turnbaugh, P.J.; Ley, R.E.; Hamady, M.; Fraser-Liggett, C.M.; Knight, R.; Gordon, J.I. The Human Microbiome Project. Nature 2007, 449, 804–810. [Google Scholar] [CrossRef]
  51. Savin, Z.; Kivity, S.; Yonath, H.; Yehuda, S. Smoking and the intestinal microbiome. Arch. Microbiol. 2018, 200, 677–684. [Google Scholar] [CrossRef]
  52. Naik, H.B.; Piguet, V. Standardizing Hidradenitis Suppurativa Skin Microbiome Research: The Methods Matter. J. Investig. Dermatol. 2020, 140, 1688–1690. [Google Scholar] [CrossRef]
  53. Bervoets, L.; Van Hoorenbeeck, K.; Kortleven, I.; Van Noten, C.; Hens, N.; Vael, C.; Goossens, H.; Desager, K.N.; Vankerckhoven, V. Differences in gut microbiota composition between obese and lean children: A cross-sectional study. Gut Pathog. 2013, 5, 10. [Google Scholar] [CrossRef]
  54. Der Sarkissian, S.; Hessam, S.; Kirby, J.S.; Lowes, M.A.; Mintoff, D.; Naik, H.B.; Ring, H.C.; Chandran, N.S.; Frew, J.W. Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review. JAMA Dermatol. 2022, 158, 300–313. [Google Scholar] [CrossRef]
  55. Ma, B.; Forney, L.J.; Ravel, J. Vaginal Microbiome: Rethinking Health and Diseases. Annu. Rev. Microbiol. 2012, 66, 371–389. [Google Scholar] [CrossRef] [PubMed]
  56. Jo, J.-H.; Kennedy, E.A.; Kong, H.H. Research Techniques Made Simple: Bacterial 16S Ribosomal RNA Gene Sequencing in Cutaneous Research. J. Investig. Dermatol. 2016, 136, e23–e27. [Google Scholar] [CrossRef] [PubMed]
  57. Kong, H.H.; Andersson, B.; Clavel, T.; Common, J.E.; Jackson, S.A.; Olson, N.D.; Segre, J.A.; Traidl-Hoffmann, C. Performing Skin Microbiome Research: A Method to the Madness. J. Investig. Dermatol. 2017, 137, 561–568. [Google Scholar] [CrossRef]
  58. Ring, H.; Bay, L.; Nilsson, M.; Kallenbach, K.; Miller, I.; Saunte, D.; Bjarnsholt, T.; Tolker-Nielsen, T.; Jemec, G. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br. J. Dermatol. 2016, 176, 993–1000. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 11 02277 g001
Figure 1. PRISMA flow diagram of study selection for inclusion in the systematic review; PRISMA—Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 1. PRISMA flow diagram of study selection for inclusion in the systematic review; PRISMA—Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Biomedicines 11 02277 g001
Table 1. Metagenomic sequencing skin studies.
Table 1. Metagenomic sequencing skin studies.
Study ID# of Patients# of Healthy ControlsSample Type16S Regionα–Diversityβ–DiversityMajor FindingsNOS
Lam 2021 [11]76swabsV3–V4no significant differencesno significant differencesMesorhizobium ↑ in lesional skin4
Schneider 2020 [22]1110swabs/cyanoacrylate
glue		V3–V4no significant differencessignificant loss in HS patients;
impact of smoking and alcohol use		loss of heterogeneity between body sites and skin niches in HS patients;
Cutibacterium ↓;
Peptoniphilus, Porphyromonas,
Agrobacterium, Pseudomonas, and Arcanobacterium ↑;
functional differences between microbiota of HS and normal skin;
metabolic pathways are influenced by different genera in normal and HS skin		8
Guet-Revillet 2017 [24]65NDswabs/biopsy/needle aspirationV1–V2NDNDanaerobes in lesional skin ↑;
Prevotella and Porphyromonas ↑;
Fusobacterium and Parvimonas—correlation with HS severity		5
McCarthy 2022 [12]5920swabsNDreduction in HS cohort (only nasal swabs reached statistically significant decrease)significant separation in beta-diversity with respect to axilla, groin, and nasal microbiota datasetsFinegoldia magna ↑ (groin and axilla) in HS9
Naik 2020 [14]125swabsV1–V3significant ↑ in the inguinal creases of HS (affected and unaffected skin)NDCutibacterium spp. ↓ in HS (affected and unaffected);
Gram negative Porphyromonadeacea, Prevotellaceae, Fusobacteria phylum + positive anaerobes (Clostridales) ↑ in HS (affected and unaffected skin)		6
Ring 2017 [18]3024biopsy (HS: lesional and non-lesional skin)V3–V4 +
V3–V4 of the 18SrDNA		no significant difference;
increased Shannon diversity index was found in non-lesional HS skin compared to lesional and healthy skin		no significant differenceCorynebacterium and Porphyromonas and Peptoniphilus—HS skin;
Acinetobacter + Morxella ↑ in non-lesional HS;
Porphyromonas and Peptoniphilus spp. at the genus level sig ↑ in lesional skin;
Cutibacterium spp. ↑ in healthy controls;
P. acnes and Corynebacterium striatum ↑ in the healthy control group		7
Guet-Revillet H 2014 [16]6NDtranscutaneous/swabsNDNDNDStaphylococcus ↑ within the Hurley stage 1 abscess;
Prevotellam Porphyromonas, Anaerococcus and Mobiluncus spp. ↑ in chronic suppurating lesions		3
Riverain-Gillet 2020 [17]6017swabsNDno significant differencesignificantly higher in HS samplesPrevotella, Actinomyces, Campylobacter ureolyticus and Mobilinucus ↑
staphylococci ↓ in HS samples;
two clusters: Cluster A—enriched in anaerobes (Prevotella, Porphyromonas, Dialister and Peptoniphilus asaccharolyticus), Cluster B—aerobic) associated with Staphylococcus and Micrococcus		7
ND—not determined.
Table 2. Culture-based skin studies.
Table 2. Culture-based skin studies.
Study ID# of Patients# of Healthy ControlsSample TypeCulture Methodsα–Diversityβ–DiversityMajor FindingsNOS
Jamalpour 2019 [25]26NDswabsstandard culture-based methodsNDNDStaphylococcus aureus, Diphtheroid, and Escherichia coli—most common2
Nikolakis 2017 [26]50NDswabs5% sheep blood agar—aerobic bacteria/Schaedler agar
+ 5% sheep blood—anaerobic bacteria		NDNDS. aureus, S. epidermidis, E. faecalis, E. coli, P.bivia, and P. disiens—most common;
Higher Hurley stages correlated with more polymicrobial flora		3
Thomas 2016 [27]76NDswabsstandard culture-based methodsNDNDCorynebacterium
Species, Staphylococcus epidermidis and Staphylococcus aureus—most common		2
Hessam 2016 [28]113NDdeep swabsstandard culture-based methodsNDNDcoagulase-negative staphylococci and Staphylococcus aureus,
Proteus mirabilis and Escherichia coli—most common;
low resistance rate for cotrimoxazole		3
Haskin 2016 [29]189NDpurulent drainage swabNCNDNDFirmicutes ↑—among obese HS patients vs. nonobese2
Matusiak 2014 [31]69NDswabsstandard culture-based methodsNDNDS. epidermidis, Proteus mirabilis, S. aureus, Enterococcus faecalis—most common;
carbapanems, penicillins with
β-lactamase inhibitors and fluoroquinolones—highest effectiveness		3
Sartorius 2012 [32]10NDswabs (superficial and deep)/skin biopsystandard culture-based methodsNDNDStaphylococcus aureus not found in any lesions;
coagulase-negative
Staphylococci, Corynebacterium spp.—most common		2
Lapins 1999 [33]25NDswabs (superficial, middle and deep)/skin biopsystandard culture-based methodsNDNDStaphylococcus aureus, coagulase-negative staphylococci, Peptostreptococcus spp., Cutibacterium acnes, S. aureus—most common3
Brook 1999 [34]17NDswabsstandard culture-based methodsNDNDS. aureus, Streptococcus pyogenes, Pseudomonas
Aeruginosa,
Peptostreptococcus
spp., Prevotella spp., micro-aerophilic
streptococci, Fusubacteriurn spp.,
Bacteroides spp.—most common		2
Jemec 1996 [35]41NDpus aspirationstandard culture-based methodsNDNDS. aureus, S. milleri, S. epidermidis, S. hominis, Corynebacterium spp., Acinetobacter spp., Lactobacillus spp.—most common3
Katoulis 2015 [15]22NDdirect percutaneous needle aspiration of abscesssheep blood (5%), chocolate and MacConkey agar plates were incubated under anaerobic conditions.NDND7 were culture negative and 15 culture positive;
16 isolates obtained (14 aerobic, 2 anaerobic);
P. mirabilis, Staphylococcus haemolyticus and Staphylococcus lugdunensis—predominant aerobic species;
Dermacoccus nishinomiyaensis and Cutibacterium granulosum—isolated anaerobic bacteria		3
Guet-Revillet H 2014 [16]82NDtranscutaneous;
swabs		anaerobic bacteria growth—homogenization of the biopsy samples using a sterile porcelain mortar in 0.5 mL of Schaedler broth,
purulent drainage and swab specimens discharged in 0.5 mL of Schaedler broth, Uriselect4 agar plate, a colistin-nalidixic acid (CNA) blood agar plate, and a Columbia blood agar plate.		NDND106 out of 126 lesional samples positive;
two microbiological profiles detected: Profile A—Staphylococcus lugdunensis as a unique or predominant isolate, Profile B—a mixed anaerobic flora of strict anaerobes and/or anaerobic actinomycetes and/or streptococci of the milleri group		3
Riverain-Gillet 2020 [17]6017NDNCNDNDS. epidermidis, Staphylococcis hominis, Cutibacterium avidum and Cutibacterinum acnes ↑ in the skinfolds of HS subject;
mean abundance of anaerobes ↑ in Hs skinfolds		7
Benzecry 2018 [21]46NDswabschocolate agar, Columbia agar with 5% sheep blood, Mannitol salt agar, MacConkey agar, Schaedler CNA agar with 5% sheep blood, Schaedler neomycin—vancomycin with 5% sheep blood agar, Columbia CNA agar with 5% sheep blood.NDND31 cultures (52%) positive;
total of 15 bacterial species isolated: nine aerobes and six anaerobes;
Enterobacteriaceae the most frequent isolates (#11 = 35%), followed by Streptococcus spp. (#8 = 26%), Corynebacterium spp. (#7 = 23%) and Staphylococcus spp. (#6 = 19%).		3
ND—not determined, NC—not clear.
Table 3. (PNA)-FISH and CLSM skin studies.
Table 3. (PNA)-FISH and CLSM skin studies.
Study ID# of Patients# of Healthy ControlsSample TypeMethodα–Diversityβ–DiversityMajor FindingsNOS
Ring 2017 [19]2424punch biopsy (clinically unaffected HS skin)PNA-FISH and CLSM examinationsNDNDabsence of bacterial aggregates at the stratum corneum and in hair follicle—preclinical HS skin;
12% of HS samples categorized as positive; morphologically significant presence of bacterial aggregates in 92% of the healthy controls		7
ND—not determined.
Table 4. FISH, histology and IF (Immunofluorescence of the skin) skin studies.
Table 4. FISH, histology and IF (Immunofluorescence of the skin) skin studies.
Study ID# of Patients# of Healthy ControlsSample Typeα–Diversityβ–DiversityMajor FindingsNOS
Jahns AC 2014 [23]37NDtissue samplesNDNDhistology: 17 patients (63%) positive for bacterial colonization;
DAPI labeled coccoids seen in 71% of the positive patients in the form of biofilms and microcolonies;
P. acnes as biofilms in hair follicles of two patients;
Staphylococcus aureus and coagulase-negative staphylococci not detected in any sample		2
ND—not determined.
Table 5. Metagenomic sequencing studies gut.
Table 5. Metagenomic sequencing studies gut.
Study ID# of Patients# of Healthy ControlsSample Type16S Regionα–Diversityβ–DiversityMajor FindingsNOS
Lam 2021 [11]1720stoolV3–V4no significant differencesno significant differencesRobinsoniella peoriensis in HS patients;
Sellimonas ↑;
Christensenellaceae ↓		4
S. Kam 2020 [36]33fecal samples from the central portion of the specimenNDno significant differences (measured with operational taxonomic unit (OUT));
significant difference: greater in the control group (measured with Shannon index)		no significant differences (measured with weighted UniFrac distance matrices)HS patients:
Firmicutes ↓
Bilophila + Holdemania ↑
Lachnobacterium + Veillonella ↓		8
Eppinga H 2016 [13]HS only = 17
concomitant HS and IBD = 17		3320 mg of fecesNDno significant differenceNCF. prausnitzii ↓ patients with IBD + HS;
no significant difference between the abundance of E. coli and HS cohorts and healthy controls		8
McCarthy 2022 [12]5930fecalNDsignificantly ↓ in HSless clustering within the HS samplesRuminococcus callidus + Eubacterium rectale ↑ in HS;
the greatest amplicon sequence variants (ASVs) assigned to the taxa Streptococcus spp. and Ruminococcus gnavus		9
Ring 2019 [20]32NDskin covering tunnelsV3–V4
+
V3–V4 18S rDNA		NDNDPorphyromonas spp. and Prevotella spp. ↑ gelatinous material in the HS tracts;
Corynebacterium, Staphylococcus, and Peptoniphilus ↑		3
ND—not determined, NC—not clear.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lelonek, E.; Bouazzi, D.; Jemec, G.B.E.; Szepietowski, J.C. Skin and Gut Microbiome in Hidradenitis Suppurativa: A Systematic Review. Biomedicines 2023, 11, 2277. https://doi.org/10.3390/biomedicines11082277

AMA Style

Lelonek E, Bouazzi D, Jemec GBE, Szepietowski JC. Skin and Gut Microbiome in Hidradenitis Suppurativa: A Systematic Review. Biomedicines. 2023; 11(8):2277. https://doi.org/10.3390/biomedicines11082277

Chicago/Turabian Style

Lelonek, Edyta, Dorra Bouazzi, Gregor B. E. Jemec, and Jacek C. Szepietowski. 2023. "Skin and Gut Microbiome in Hidradenitis Suppurativa: A Systematic Review" Biomedicines 11, no. 8: 2277. https://doi.org/10.3390/biomedicines11082277

APA Style

Lelonek, E., Bouazzi, D., Jemec, G. B. E., & Szepietowski, J. C. (2023). Skin and Gut Microbiome in Hidradenitis Suppurativa: A Systematic Review. Biomedicines, 11(8), 2277. https://doi.org/10.3390/biomedicines11082277

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop